Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNX-1300 for Acute Cocaine Intoxication
NCT06045793Phase 2Terminated
- Sponsor
- Tonix Pharmaceuticals
- Start
- Aug 2024
- Primary completion
- Apr 2025
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in Acute cocaine intoxication comparing TNX-1300 with Placebo + Usual Care (2 arms). Primary endpoint: Change from Baseline in Systolic Blood Pressure. Started Aug 2024; status: terminated.
02
Drugs
TNX-1300
03
Conditions
Acute cocaine intoxication
Beyond the preview
Go deeper on NCT06045793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06045793.